secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0001437749-23-015914
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech annual meeting: authorized share increase fails, reverse split postponed
--------------------------------------------------------------------------------

- Shareholders rejected increase in authorized shares from 100M to 200M (11.4M for, 7.6M against).
- Reverse stock split proposal (Proposal 5) adjourned to June 15, 2023; meeting postponed to solicit proxies.
- Super-majority voting elimination failed; needed 2/3 of outstanding shares but had only ~9.3M for.
- Stockholders approved increase in shares under 2015 Stock Plan (8.4M for, 4.0M against).
- All six directors elected; Grant Thornton LLP ratified as auditor (17.3M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923015914/0001437749-23-015914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923015914/mbrx20230524_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-015914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer